Biogen Exits Joint Venture As Samsung Biologics Buys Out Bioepis
Sale Price Of $2.3bn To Be Paid Over Next Two Years
Executive Summary
Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.
You may also be interested in...
Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.
Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.
Biogen Reiterates Byooviz Will Not Be Meaningful In 2022
Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.